CACNB1
ENSG00000067191
Target class
Auxiliary transport protein
Chromosome
17
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNB1
- Gene name
- Calcium voltage-gated channel auxiliary subunit beta 1
- Gene symbol
- CACNB1
- Previous gene symbols
- CACNLB1
- Protein name
- Voltage-dependent L-type calcium channel subunit beta-1 (CAB1) (Calcium channel voltage-dependent subunit beta 1)
- Gene biotype
- Protein coding
- Gene family
- Membrane associated guanylate kinases|Calcium voltage-gated channel auxiliary beta subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Highest tissue expression
- 96.7
- Tissue specificity (Gini)
- 0.467
- Tissue specificity (tau)
- 0.859
- KEGG gene identifiers
- hsa:782
- Protein interaction confidence
- 0.883407
- Protein interaction partners
- 27
- R-HSA-112308
- R-HSA-419037
- R-HSA-5576892
- R-HSA-5576893
- R-HSA-9856532
- End position
- 39197723
- Start position
- 39173453
- Chromosome
- 17
- Strand
- Reverse
- Cell membrane, sarcolemma
- Peripheral membrane protein
- Cytoplasmic side . Cell membrane
- Peripheral membrane protein .
- PubMed 15615847
- PubMed 1309651
- Tissue specificity (tau)
- 0.859373
- Expression inequality (Gini)
- 0.4667
Expression in transcripts per million
- Muscle - Skeletal
- 96.7
- Brain - Frontal Cortex (BA9)
- 56.07
- Brain - Cortex
- 49.55
- Brain - Anterior cingulate cortex (BA24)
- 34.71
- Brain - Cerebellar Hemisphere
- 29.82
Expression in transcripts per million
- Muscle - Skeletal96.7
- Brain - Frontal Cortex (BA9)56.07
- Brain - Cortex49.55
- Brain - Anterior cingulate cortex (BA24)34.71
- Brain - Cerebellar Hemisphere29.82
- Brain - Cerebellum29.22
- Brain - Nucleus accumbens (basal ganglia)28.84
- Brain - Caudate (basal ganglia)25.83
- Artery - Tibial24.97
- Brain - Hippocampus21.99
- Brain - Hypothalamus21.54
- Brain - Putamen (basal ganglia)20.08
- Brain - Amygdala20.03
- Artery - Aorta19.01
- Skin - Sun Exposed (Lower leg)18.7
- Cervix - Endocervix17.03
- Testis16.68
- Skin - Not Sun Exposed (Suprapubic)15.14
- Lung15.13
- Thyroid14.06
- Pituitary13.82
- Nerve - Tibial13.67
- Artery - Coronary13.39
- Fallopian Tube12.59
- Cervix - Ectocervix11.97
And 29 more, listed on the interactive page.
- GO:1902514
- GO:1904646
- GO:0005886
- GO:0005891
- GO:0005245
- GO:0005246
- GO:0005515
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker